Dr. Yaqian Han 韩亚骞
Chief Physician
Department of Head and Neck Radiation Oncology II, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation and comprehensive treatment for nasopharyngeal, oral, oropharyngeal, hypopharyngeal, laryngeal, nasal sinus cancers, CNS tumors such as gliomas, and breast cancer.
Dr. Han is Chief of the Second Department of Head and Neck Radiotherapy at Hunan Cancer Hospital and Director of the Hunan Nasopharyngeal Cancer Precision Treatment Clinical Medical Center. In 2016, Dr. Han studied proton radiotherapy in Munich, Germany. Research has been presented at ASCO and ASTRO. Dr. Han has published over 40 papers, including more than 30 SCI articles, and contributed to four oncology radiotherapy monographs and clinical guidelines.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Nasopharyngeal Cancer Professional Committee, China Anti-Cancer Association
- Chair, Nasopharyngeal Cancer Professional Committee, Hunan Anti-Cancer Association
- Member, Head and Neck Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Han Yaqian). Papers usually list the name as Yaqian Han or Han Y.
Selected publications
69 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization. PubMed 42433378
- Cell Oncol (Dordr), 2025 (first author): Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential. PubMed 40601247
- Heliyon, 2024 (first author): Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin. PubMed 39397900
- Cancer Med, 2024 (senior author): Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy. PubMed 38156901
- Radiat Oncol, 2022 (senior author): Characteristics of locoregional extension of unilateral nasopharyngeal carcinoma and suggestions for clinical target volume delineation. PubMed 35279160
- Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2022 (senior author): Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma. PubMed 35545406
- J Nanosci Nanotechnol, 2020 (first author): Radiosensitivity Effect of Epidermal Growth Factor Receptor Nanoparticles on Head and Neck Squamous Cell Carcinoma. PubMed 32384946
- J Cancer, 2019 (first author): High expression of calreticulin indicates poor prognosis and modulates cell migration and invasion via activating Stat3 in nasopharyngeal carcinoma. PubMed 31632490
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion